Associated Genetic Biomarkers
NCI Definition: A morphologic variant of chondrosarcoma arising from bone and soft tissue. It is characterized by the presence of malignant small round cells, biphasic growth pattern, and well differentiated hyaline cartilage. Clinical presentation includes pain and swelling. The clinical course is aggressive, with local recurrences and distant metastases. 
Mesenchymal chondrosarcomas most frequently harbor alterations in NCOA2, ATRX, INSR, HEY1, and YES1 .
NCOA2 Fusion, ATRX Mutation, INSR T557M, HEY1-NCOA2 Fusion, and YES1 Amplification are the most common alterations in mesenchymal chondrosarcoma .
There are 3 clinical trials for mesenchymal chondrosarcoma, of which 3 are open and 0 are completed or closed. Of the trials that contain mesenchymal chondrosarcoma as an inclusion criterion, 1 is phase 1/phase 2 (1 open) and 2 are phase 2 (2 open).
HEY1-NCOA2 is the most frequent gene inclusion criterion for mesenchymal chondrosarcoma clinical trials .
Enb003, pembrolizumab, and placebo are the most common interventions in mesenchymal chondrosarcoma clinical trials.
Significant Genes in Mesenchymal Chondrosarcoma
HEY1 is altered in 40.0% of mesenchymal chondrosarcoma patients .
HEY1 is an inclusion eligibility criterion in 1 clinical trial for mesenchymal chondrosarcoma, of which 1 is open and 0 are closed. Of the trial that contains HEY1 status and mesenchymal chondrosarcoma as inclusion criteria, 1 is phase 2 (1 open) .
NCOA2 is altered in 60.0% of mesenchymal chondrosarcoma patients .
NCOA2 is an inclusion eligibility criterion in 1 clinical trial for mesenchymal chondrosarcoma, of which 1 is open and 0 are closed. Of the trial that contains NCOA2 status and mesenchymal chondrosarcoma as inclusion criteria, 1 is phase 2 (1 open) .
2. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 8. This dataset does not represent the totality of the genetic landscape; see paper for more information.